(Stroke. 1999;30:780-786.)
© 1999 American Heart Association, Inc.
Original Contributions |
From the Departments of Neurology (S.A.M., L.L., M.E.F., L.M.K.), Medicine (J.L., S.H., D.S.), and Neurosurgery (R.A.S., A.B.), ColumbiaPresbyterian Medical Center, New York, NY.
Correspondence and reprint requests to Dr Stephan A. Mayer, Division of Critical Care Neurology, Neurological Institute, 710 West 168th St, Box 39, New York, NY 10032. E-mail sam14{at}columbia.edu
| Abstract |
|---|
|
|
|---|
MethodsWe retrospectively studied 72 patients admitted to our neuro-ICU for aneurysmal subarachnoid hemorrhage over a 2.5-year period. We selected patients who met the following criteria: (1) CK-MB levels measured within 3 days of onset, (2) pulmonary artery catheter placed, (3) echocardiogram performed, and (4) no history of preexisting cardiac disease. Hemodynamic profiles were recorded on the day after surgery (n=67) or on the day of echocardiography (n=5) if surgery was not performed (mean, 3.3±1.7 days after onset). The severity of cardiac injury was classified as none (peak CK-MB <1%, n=36), mild (peak CK-MB 1% to 2%, n=21), moderate (peak CK-MB >2%, n=6), or severe (abnormal left ventricular wall motion, n=9).
ResultsAbnormal left ventricular wall motion occurred exclusively in patients with peak CK-MB levels >2% (P<0.0001), poor neurological grade (P=0.002), and female sex (P=0.02). Left ventricular stroke volume index and stroke work index were elevated above the normal range in patients with peak CK-MB levels <1% and fell progressively as the severity of cardiac injury increased, with mean values for patients with abnormal wall motion below normal (both P<0.0001 by ANOVA). Cardiac index followed a similar trend, but the effect was less pronounced (P<0.0001). Using forward stepwise multiple logistic regression, we found that thick subarachnoid clot on the admission CT scan (odds ratio, 1.9; 95% confidence interval [95% CI], 1.0 to 3.4; P=0.04) and depressed cardiac index (odds ratio, 2.1; 95% CI, 1.0 to 4.1; P=0.04) were independent predictors of symptomatic vasospasm.
ConclusionsMyocardial enzyme release and echocardiographic wall motion abnormalities are associated with impaired left ventricular performance after subarachnoid hemorrhage. In severely affected patients, reduction of cardiac output from normally elevated levels may increase the risk of cerebral ischemia related to vasospasm.
Key Words: cardiac output cardiovascular diseases creatine kinase isoenzymes echocardiography subarachnoid hemorrhage vasospasm
| Introduction |
|---|
|
|
|---|
Neurogenic ECG changes after SAH are usually regarded as asymptomatic, primarily because serious cardiac arrhythmias in the hospital occur in only 1% to 4% of patients.16 17 The potential impact of neurogenic cardiac injury on left ventricular hemodynamic performance after SAH has received little attention but may have important implications because approximately 30% of patients develop delayed cerebral ischemia related to vasospasm. Clinical studies in humans indicate that vasospasm is associated with a loss of autoregulation,18 and experimental studies have shown that cerebral blood flow (CBF) in ischemic areas can vary passively with changes in blood pressure19 and cardiac output.19 20 Accordingly, hypovolemia has been implicated as a risk factor for symptomatic vasospasm,21 22 and augmentation of blood pressure and cardiac output can reverse ischemic deficits in affected patients.23 24 25
We performed this study to determine (1) whether myocardial injury after SAH adversely affects left ventricular contractility and (2) whether depressed baseline cardiovascular hemodynamic performance is a risk factor for delayed cerebral ischemia related to vasospasm.
| Subjects and Methods |
|---|
|
|
|---|
One hundred and ninety-two patients were admitted to the NICU with SAH during the 2.5-year study period. We excluded 46 patients who were admitted 4 or more days after hemorrhage, 26 who had a normal angiogram or died before angiography could be performed, and 14 who had a history of preexisting cardiac disease (coronary artery disease, valvular heart disease, or arrhythmia). Of the remaining 106 potentially eligible patients, 34 (32%) were excluded because echocardiography, CK-MB, or PAC data were not obtained, leaving 72 subjects for analysis. Forty-six of these patients were enrolled in the hypervolemia/normovolemia CBF trial, 55 were included in a previous study analyzing the relationship between ECG changes and echocardiographic abnormalities after SAH,3 and 3 were included in a series of SAH patients with neurogenic pulmonary edema and coexisting echocardiographic left ventricular dysfunction.13 Because this study was conducted as a retrospective analysis and did not compromise patient confidentiality, formal review was waived by the Institutional Review Board.
Management Protocol and Data Collection
Data were obtained from hospital records and a prospectively
maintained NICU database. Neurological status on admission was rated
according to the modified Hunt-Hess scale,28 and the
amount of blood on admission CT scans was graded by a blinded
radiologist using the Fisher scale.29 Aneurysm
location was classified as anterior cerebral (including anterior
communicating artery), internal carotid (including posterior
communicating artery), middle cerebral, or vertebrobasilar.
Symptomatic vasospasm was recognized by focal neurological
signs or deterioration in level of consciousness, with either
confirmation of infarction by CT or exclusion of other possible causes
of deterioration (eg, rebleeding, hydrocephalus, edema, electrolyte
disorder, infection, seizure).30 Symptomatic
vasospasm was diagnosed by physicians (R.A.S. and L.L.) who were
blinded to the cardiovascular
hemodynamic data. Patients were evaluated on admission
for the presence of pulmonary edema, defined by the presence of
characteristic diffuse infiltrates on chest radiography
and reduced oxygenation requiring at least 40%
supplemental oxygen, and hypotension, defined as a systolic
blood pressure <100 mm Hg requiring treatment with
intravenous pressors; noncardiac causes of
pulmonary infiltrates, hypoxemia, or hypotension were
rigorously excluded.
All patients were managed according to a standard protocol,31 whether or not they were enrolled in the hypervolemia/normovolemia CBF study. Surgical clipping of the aneurysm was performed within 48 hours of admission, except in 5 patients who were medically or neurologically too unstable for surgery. All patients received 80 mL/h of 5% dextrose and 0.9% saline pre- and postoperatively, with additional isotonic crystalloid provided as clinically indicated. Total fluid input on the day of surgery ranged from 4 to 6 L, resulting in a mildly volume-expanded state on the first postoperative day.27 After a baseline cardiovascular hemodynamic profile was measured on the morning after surgery, 250 mL of 5% albumin solution was given every 2 hours if the pulmonary artery diastolic pressure (PADP) was less than or equal to the following target values: hypervolemic therapy, 14 mm Hg; normovolemic therapy, PADP 7 mm Hg. Treatment was determined by random assignment for patients enrolled in the hypervolemia/normovolemia CBF study; otherwise, target cardiac filling pressures were determined by the attending physician. All patients received nimodipine (60 mg orally every 4 hours), and most were treated with phenytoin and dexamethasone during the perioperative period.
Cardiovascular hemodynamic profiles were measured once a day by a single investigator (S.A.M.) and recorded in an NICU database. We analyzed hemodynamic profiles on the first postoperative day in the patients who underwent surgery (before assignment to normovolemic or hypervolemic therapy) to control for variations in volume status or on the day that echocardiography was performed in the 5 nonoperated patients. Mean arterial blood pressure (MABP), central venous pressure (CVP), PADP, and pulmonary artery wedge pressure (PAWP) were measured using saline-filled catheters with transducers positioned at the level of the right atrium. Cardiac output was measured with a PAC using the iced-saline thermodilution technique. Three measurements were obtained and the average value recorded, with outlying values (>500 mL/min) discarded if necessary. Injections were not timed with respect to the ventilatory cycle. Cardiac index (CI), systemic vascular resistance index (SVRI), left ventricular stroke volume index (LVSVI), and left ventricular stroke work index (LVSWI) were calculated according to standard formulae.32 Three patients received vasopressors (dopamine or phenylephrine) at the time the hemodynamic profile was recorded, in 1 patient for hypotension and in 2 patients for symptomatic vasospasm.
Serum CK levels were obtained daily for 3 days on admission to the NICU and approximately every other day thereafter. CK isoenzyme fractionation was performed using agarose gel electrophoresis (Paragon system; Beckman) on all values above normal range (0 to 50 U/L). MB fractions between 2% and 5% are classified as borderline in our laboratory, with values above 5% considered diagnostic of myocardial infarction.
Two-dimensional color-flow Doppler transthoracic echocardiography was performed in the NICU using Hewlett-Packard Sonos 1000 equipment (Hewlett-Packard Imaging Systems Division). All initial studies were performed within 3 days of admission, and most patients underwent a repeat examination 4 to 6 days after the first study. Standard parasternal long axis, short axis, and apical 2- and 4-chamber views were obtained for analysis of left ventricular function. Echocardiograms were reviewed by a cardiologist blinded to the clinical status of the patient using a standardized evaluation form (Cardioscan Inc.). Wall motion was classified as normal, hypokinetic, akinetic, or dyskinetic in each of 14 anatomic segments. The left ventricular ejection fraction was visually estimated as normal (50% to 70%) or mildly (40% to 50%), moderately (30% to 40%), or severely (<30%) reduced.
Statistical Analysis
Peak preoperative CK-MB levels and
echocardiography results were used to classify the
extent of cardiac injury into 4 categories: (1) none, peak
CK-MB<1%; (2) mild, peak CK-MB 1% to 2%; (3) moderate, peak
CK-MB>2%; and (4) severe, wall motion abnormality present on
echocardiography. Factorial ANOVA was used to
compare continuous variables between the 4 groups, and the
Bonferroni/Dunn procedure was used for post-hoc analysis of
between-group differences. Proportions were compared using the
2 test or Fisher's exact test, and mean
values were compared using the 2-tailed t test.
Variables with P<0.05 in a univariate
analysis of risk factors for symptomatic vasospasm
were entered into a forward stepwise multivariate
logistic regression model to identify those with an independent
association. Data analysis was performed using commercially
available statistical software (Statview 4.5, Abacus Concepts and SPSS
version 6.01, SPSS Inc.). Significance was judged at the
P<0.05 level, with Bonferroni correction for multiple
comparisons within each analysis.
| Results |
|---|
|
|
|---|
|
Peak CK-MB levels were <1% in 36 patients (50%), 1% to 2% in 21 patients (29%), and >2% in 15 patients (21%). The mean interval from SAH to peak CK-MB in the 36 patients with detectable levels was 1.4±1.3 days. Admission total serum CK levels (mean 216±272 U/L; range, 23 to 1520 U/L) did not differ based on peak CK-MB levels.
Echocardiography revealed abnormal left ventricular wall motion in 9 patients (13%). Abnormal wall motion occurred exclusively in patients with peak CK-MB levels >2% (9/15 versus 0/57, P<0.0001), Hunt/Hess grades of III to V (9/36 versus 0/36, P=0.002), and female sex (9/47 versus 0/25, P=0.02), and all but 1 affected patient had an admission CT Fisher grade of III or IV (8/36 versus 1/36, P=0.03; significance judged at P<0.0125 using Bonferroni correction). There was no relationship between aneurysm location or laterality and abnormal left ventricular wall motion.
Within 6 hours of onset of SAH, 1 patient with abnormal wall motion developed severe hypotension, 1 developed pulmonary edema, and 4 developed both; none of the patients with normal echocardiograms experienced these complications. Peak CK levels in the 9 patients with abnormal wall motion ranged from 116 to 1520 U/L (mean, 375 U/L), and CK-MB levels ranged from 2.0% to 10.5% (mean, 3.8%). Left ventricular ejection fractions were graded as mildly reduced (40% to 50%) in 2 patients, moderately reduced (30% to 40%) in 5 patients, and severely reduced (20% to 30%) in 2 patients. All 5 patients who underwent serial echocardiography 6 to 44 days after SAH had normalization of their ejection fractions, and all 9 patients had widespread T-wave inversions and QTc prolongation (>440 ms) on at least 1 ECG. Requests for autopsy examination of 3 patients with abnormal wall motion who died were refused.
Among the study group as a whole, indicators of cardiac preload (CVP,
PADP, PAWP) and left ventricular performance
(LVSVI, LVSWI) were elevated, mean CI was at the high end of the normal
range, and SVRI was slightly below the normal range (Table 2
). Mean values for LVSVI (see the
Figure
, A) and LVSWI (see the Figure
,
B) were elevated above the normal range in patients with no
evidence of cardiac injury (peak CK-MB levels <1%) and showed
progressive reduction as the severity of cardiac injury increased, with
values for patients with abnormal left ventricular wall
motion below normal (both P<0.0001). A similar but less
pronounced trend (see the Figure
, C) was also seen for CI
(P<0.0001). SVRI was significantly elevated in patients
with abnormal wall motion (P=0.0001 by ANOVA), and a trend
toward higher mean PADP in patients with abnormal wall motion was near
significance (P=0.006). The extent of cardiac injury had no
significant effect on heart rate, MABP, CVP, or PAWP, and there were no
significant differences in mean age, admission CK levels, day of
measurement of cardiovascular
hemodynamic data, or day of
echocardiography between the 4 groups.
|
|
Twenty-six (36%) of the 72 study patients developed
symptomatic vasospasm. An admission CT Fisher grade of III
or IV (P<0.001), depressed CI (P<0.001),
elevated SVRI (P=0.002), depressed LVSVI
(P=0.022), and peak CK-MB >2% (P=0.039) were
associated with symptomatic vasospasm in a
univariate analysis (Table 3
). In a forward stepwise logistic
regression analysis (likelihood ratio statistic, 77; model
2, 17.0; P=0.0002 for the entire
model), Fisher CT grade III or IV (coded +1.0=yes, -1.0=no, logistic
coefficient 0.6292, odds ratio 1.88, 95% confidence interval 1.02 to
3.43, P=0.041) and CI (logistic coefficient -0.7189, odds
ratio 2.05, 95% confidence interval 1.03 to 4.09 for each 1.0 L
· min-1 · m-2
reduction, P=0.041) were identified as independent
predictors of symptomatic vasospasm.
|
| Discussion |
|---|
|
|
|---|
We excluded patients with preexisting heart disease from this study to
avoid cardiac enzyme or echocardiographic abnormalities
related to nonneurogenic mechanisms. Indices of cardiac preload (PADP
and PAWP) and left ventricular performance (CI,
LVSVI, and LVSWI) were elevated in our subjects on the first
postoperative day (mean, 3.3 days after SAH), indicative of a
volume-expanded and hyperdynamic cardiovascular state
(Table 2
). Others have reported similar findings in SAH patients
treated with volume expansion,23 24 33 in contrast to
patients with ischemic stroke, who have higher MABPs and lower
cardiac outputs with equivalent cardiac filling
pressures.34 Mean SVRI was slightly below the normal range
in our patients, which may have resulted in part from the
administration of nimodipine, a peripheral vasodilator.
CK-MB elevation was detected in half of our patients, and peak CK-MB fractions exceeded 2% in one fifth of patients, a finding consistent with previous studies.3 4 5 Abnormal left ventricular wall motion was slightly more common in our patients (13%, 9/72 patients) than in 3 other echocardiographic studies of SAH, which found a combined frequency of abnormal wall motion of 9% (17/184).11 14 15 All 9 patients with abnormal wall motion had widespread T-wave inversions and QTc prolongation (>440 ms) on at least 1 ECG, an association that we have previously reported.3 Wall motion was abnormal only in patients with peak CK-MB levels >2%, poor admission clinical grade (Hunt/Hess grade III to V), and female sex (all P<0.02). Others have also found significant associations between abnormal wall motion, poor neurological grade,11 14 15 and CK-MB elevation14 15 after SAH. The association of left ventricular dysfunction with female sex was of borderline significance but is in agreement with reports describing a striking preponderance of females among patients with abnormal wall motion after SAH (28/31 cases), for reasons unknown.11 12 13 14 15 35 36 37 38
Our main finding is the association of CK-MB release and abnormal left
ventricular wall motion with impaired left
ventricular hemodynamic
performance. Indicators of left ventricular
performance (LVSVI, LVSWI, and CI) were abnormally high in
patients with no CK-MB release, and these measures fell progressively
as the severity of cardiac injury increased (see the Figure
). In
patients with abnormal wall motion, mean LVSVI and LVSWI were well
below the normal range, CI was at the lower limit of normal, and SVRI
was highly elevated (all P
0.0001). PADP and PAWP were also
increased in these patients, consistent with left
ventricular failure. These results suggest that activation
of the sympathetic nervous system after SAH typically results in a
hyperdynamic cardiovascular state and that even small
myocardial enzyme elevations reflect relative cardiac decompensation
and failure of the left ventricle to meet these inotropic demands. By
increasing afterload and further increasing the work of the heart,
intense peripheral vasoconstriction may play a role in
precipitating severe left ventricular decompensation with
impaired contractility. Indeed, before the onset
of hypotension and pulmonary edema, some of our patients
with abnormal wall motion had severe hypertension and transient lactic
acidosis attributed to massive peripheral
vasoconstriction.13
Contraction band necrosis is the most likely cause of the wall motion abnormalities seen in our patients. This reversible form of cardiac pathology is found in up to 50% of patients with fatal SAH at autopsy6 7 8 and results from excessive exposure to catecholamines and cellular calcium entry, leading to a hypercontracted state.8 39 Impaired myocardial contractility related to contraction band necrosis occurs in animals after excessive cardiac sympathetic stimulation,40 and decompensation of the augmented cardiovascular hemodynamic response to SAH has been produced experimentally.41 Among the 9 patients with abnormal wall motion, peak CK-MB values were relatively small compared with the severity of left ventricular dysfunction, which may be characteristic of contraction band necrosis.3 Although previously asymptomatic coronary artery disease may have been present in some of our subjects, it is clear that coronary artery disease is not required to produce the pattern of myocardial injury seen in our patients. Normal coronary arteries have been found in the vast majority of SAH patients with left ventricular hypokinesis after SAH studied by angiography or autopsy.12 13 14 15 35 36 37 38
We identified severity of SAH on the admission CT scan (Fisher grade III or IV) and depressed CI measured on the first postoperative day as independent predictors of clinical deterioration related to vasospasm. In addition to the extent of blood on CT, which is the most powerful determinant of symptomatic vasospasm,29 42 43 44 45 46 younger age,42 poor clinical grade,42 46 angiographic vasospasm,43 early surgery,43 treatment with antifibrinolytics,44 46 preexisting hypertension,43 and cigarette smoking45 have been previously identified as risk factors for delayed ischemia after SAH. Larger studies that account for all of these variables are required to determine the relative importance of baseline cardiovascular hemodynamic status as a risk factor for symptomatic vasospasm.
The retrospective design, relatively small sample size, and lack of a control group are limitations of this study. Because we required early determination of CK-MB levels, placement of a PAC, echocardiography, and no preexisting cardiac disease, we obtained data in only 68% (72/106) of potentially eligible subjects admitted to our neuro-ICU during the 2.5-year study period. Our inclusion criteria may have led to selection bias and overrepresentation of patients with acute cardiac disturbances. Analysis of a larger sample of consecutively studied subjects would determine more accurately the true frequency of left ventricular dysfunction after SAH, which may have been as low as 4.6% (9/192) during the study period. A control group of patients undergoing elective clipping of unruptured aneurysms would have been desirable, but invasive hemodynamic monitoring is not routinely performed in these patients. Nonetheless, we feel that these limitations do not invalidate our main findings.
In summary, we found that myocardial injury after SAH is associated with impaired left ventricular performance and that reduction of cardiac output in severely affected patients may increase the risk of delayed ischemia from vasospasm. Although we presume the pathogenesis of myocardial injury to be neurogenic in the majority of cases, regardless of cause, our results suggest that SAH patients with significantly reduced cardiac output at baseline may benefit from prophylactic hemodynamic augmentation to minimize the risk of developing delayed cerebral ischemia. Further research is required to confirm the relationship between myocardial injury and impaired hemodynamic performance found in our study and to determine the optimal treatment of cardiac injury in acute SAH.
| Acknowledgments |
|---|
Received October 29, 1998; revision received December 7, 1998; accepted December 7, 1998.
| References |
|---|
|
|
|---|
2. Salvati M, Cosentino F, Artico M, Ferrari M, Franchi D, Domenicucci M, Ramundo Orlando E, Tacconi L, Cosentino F Jr. Electrocardiographic changes in subarachnoid hemorrhage secondary to cerebral aneurysm: report of 70 cases. Ital J Neurol Sci. 1992;13:409413.[Medline] [Order article via Infotrieve]
3. Mayer SA, LiMandri G, Homma S, Sherman D, Fink ME, DiTullio M, Lennihan L, Beckford A, Klebanoff LM, Solomon RA. Electrocardiographic markers of abnormal left ventricular wall motion in acute subarachnoid hemorrhage. J Neurosurg. 1995;83:889896.[Medline] [Order article via Infotrieve]
4.
Fabiyani G, Hunt D, McKinley L. Myocardial creatine
kinase isoenzyme in serum after acute subarachnoid
hemorrhage. J Neurol Neurosurg Psychiatry. 1977;40:818820.
5. Hunt D, McRae C, Zapf P. Electrocardiographic and serum enzyme changes in subarachnoid hemorrhage. Am Heart J. 1969;77:479488.[Medline] [Order article via Infotrieve]
6. Doshi R, Neil-Dwyer G. A clinicopathological study of patients following a subarachnoid hemorrhage. J Neurosurg. 1980;52:295301.[Medline] [Order article via Infotrieve]
7. Greenhoot JH, Reichenbach DD. Cardiac injury and subarachnoid hemorrhage: a clinical, pathological, and physiological correlation. J Neurosurg. 1969;30:521531.[Medline] [Order article via Infotrieve]
8.
Kolin A, Norris J. Myocardial damage from acute
cerebral lesions. Stroke. 1984;15:990993.
9.
Elrifai AM, Bailes JE, Shih SR, Dianzumba S, Brillman
J. Characterization of the cardiac effects of acute
subarachnoid hemorrhage in dogs. Stroke. 1996;27:737742.
10. Burch GE, Sun SC, Calcolough H, De Pasquale NP, Sohal RS. Acute myocardial lesions following experimentally induced intracranial hemorrhage in mice: a histologic and histochemical study. Arch Pathol. 1967;84:517521.[Medline] [Order article via Infotrieve]
11.
Davies KR, Gelb AW, Manninen PH, Boughner DR, Bisnaire
D. Cardiac function in aneurysmal subarachnoid
haemorrhage: a study of electrocardiographic and
electrocardiographic abnormalities. Br J Anaesth. 1991;67:5863.
12. Kono T, Morita H, Kuroiwa T, Onaka H, Takatsuka H, Fujiwara A. Left ventricular wall motion abnormalities in patients with subarachnoid hemorrhage: neurogenic stunned myocardium. J Am Coll Cardiol. 1994;24:636639.[Abstract]
13.
Mayer SA, Fink ME, Homma S, Sherman D, Lennihan L,
Solomon RA, Klebanoff LM, Beckford A, Raps EC. Cardiac injury
associated with neurogenic pulmonary edema following
subarachnoid hemorrhage. Neurology. 1994;44:815820.
14. Pollick C, Cujec B, Parker S, Tator C. Left ventricular wall motion abnormalities in subarachnoid hemorrhage: an echocardiographic study. J Am Coll Cardiol. 1988;12:600605.[Abstract]
15. Sato K, Masuda T, Kikuno T, Kobayashi A, Ikeda Y, Ohwada T, Kikawada R. Left ventricular asynergy and myocardial necrosis accompanied by subarachnoid hemorrhage: contribution of neurological pulmonary edema [Japanese]. J Cardiol. 1990;20:359367.[Medline] [Order article via Infotrieve]
16. Solenski N, Haley C, Kassell NF, Kongable G, Germanson T, Truskowski L, Torner JC, for the participants of the Multicenter Cooperative Aneurysm Study. Medical complications of aneurysmal subarachnoid hemorrhage: a report of the Multicenter Cooperative Aneurysm Study. Crit Care Med. 1995;23:10071017.[Medline] [Order article via Infotrieve]
17.
Andreoli A, Di Pasquale G, Pinelli G, Grazi P, Tognetti
F, Testa C. Subarachnoid hemorrhage: frequency and
severity of cardiac arrhythmias. Stroke. 1987;18:558564.
18. Dernbach PD, Little JR, Jones SC, Ebrahim ZY. Altered cerebral autoregulation and CO2 reactivity after aneurysmal subarachnoid hemorrhage. Neurosurgery. 1988;22:822826.[Medline] [Order article via Infotrieve]
19. Davis DH, Sundt TM Jr. Relationship of cerebral blood flow to cardiac output, mean arterial pressure, blood volume, and alpha and beta blockade in cats. J Neurosurg. 1980;52:745754.[Medline] [Order article via Infotrieve]
20. Tranmer BI, Keller TS, Kindt GW, Archer D. Loss of cerebral regulation during cardiac output variations in focal cerebral ischemia. J Neurosurg. 1992;77:253259.[Medline] [Order article via Infotrieve]
21. Solomon RA, Post KD, McMurtry JG. Depression of circulating blood volume after subarachnoid hemorrhage: implications for treatment of symptomatic vasospasm. Neurosurgery.. 1984;15:354361.[Medline] [Order article via Infotrieve]
22. Wijdicks EFM, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol.. 1985;18:137140.
23. Levy ML, Gianotta SL. Cardiac performance indices during hypervolemic therapy for cerebral vasospasm. J Neurosurg. 1991;75:2731.[Medline] [Order article via Infotrieve]
24.
Miller JA, Dacey RG, Diringer MN. Safety of
hypertensive hypervolemic therapy with phenylephrine in the
treatment of delayed ischemic deficits after
subarachnoid hemorrhage. Stroke. 1995;26:22602266.
25. Levy ML, Rabb CH, Zelman V, Gianotta SL. Cardiac performance enhancement from dobutamine in patients refractory to hypervolemic therapy for cerebral vasospasm. J Neurosurgery. 1993;79:494499.[Medline] [Order article via Infotrieve]
26. Lennihan L, Solomon RA, Beckford AR, Fink M, Paik LM, Klebanoff LM, Mayer SA. Comparison of effects of hypervolemia and normovolemia on cerebral blood flow after subarachnoid hemorrhage. Stroke. 1997;249. Abstract.
27. Mayer SA, Solomon RA, Fink ME, Lennihan L, Thomas CE, Stern L, Beckford A, Klebanoff LM. Effect of 5% albumin solution on sodium balance and blood volume after subarachnoid hemorrhage. Neurosurgery. 1998;42:759768.[Medline] [Order article via Infotrieve]
28. Hunt WE, Hess RM. Surgical risk as related to time of intervention in the repair of intracranial aneurysms. J Neurosurg. 1968;28:1420.[Medline] [Order article via Infotrieve]
29. Fisher CM, Kistler JP, Davis JM. Relation of cerebral vasospasm to subarachnoid hemorrhage visualized by computerized tomographic scanning. Neurosurgery. 1980;6:19.[Medline] [Order article via Infotrieve]
30. Van Gijn J, Bromberg JEC, Lindsay KW, Hasan D, Vermeulen M. Definition of initial grading, specific events, and overall outcome in patients with aneurysmal subarachnoid hemorrhage: a survey. Stroke.. 1994;25:16231627.[Abstract]
31. Solomon RA, Fink ME, Lennihan L. Early aneurysm surgery and prophylactic hypervolemic hypertensive therapy for the treatment of aneurysmal subarachnoid hemorrhage. Neurosurgery. 1988;23:699704.[Medline] [Order article via Infotrieve]
32. Marik P. The ICU Therapeutics Handbook. New York: Mosby; 1996:77.
33.
Mori K, Arai H, Nakajima K, Tajima A, Maeda M.
Hemorheological and hemodynamic analysis of
hypervolemic hemodilution therapy for cerebral vasospasm after
subarachnoid hemorrhage. Stroke. 1995;26:16201626.
34.
Grotta JC, Pettigrew LC, Allen S, Tonnesen A, Yatsu FM,
Gray J, Spydell J. Baseline hemodynamic state and
response to hemodilution in patients with acute cerebral
ischemia. Stroke. 1985;16:790795.
35. Pinto RJ, Goyal V, Sharma S, Bhagwati SN. Transient myocardial dysfunction in a patient with subarachnoid haemorrhage. Int J Cardiol. 1994;46:289291.[Medline] [Order article via Infotrieve]
36.
Yasu T, Owa M, Omura N, Katsuki T, Saito M. Transient
ST elevation and left ventricular asynergy associated with
normal coronary artery in aneurysmal
subarachnoid hemorrhage. Chest. 1993;103:12741275.
37. Asplin BR, White RD. Subarachnoid hemorrhage: atypical presentation with rapidly changing cardiac arrhythmias. Am J Emerg Med. 1994;12:370373.[Medline] [Order article via Infotrieve]
38. Handlin LR, Kindred LH, Beauchamp GD, Vacek JL, Rowe SK. Reversible left ventricular dysfunction after subarachnoid hemorrhage. Am Heart J. 1993;126:235240.[Medline] [Order article via Infotrieve]
39. Samuels MA. Electrocardiographic manifestations of neurologic disease. Semin Neurol. 1984;4:453461.
40. Pilati CF, Clark RS, Gillteaux J, Bosso FJ, Holcomb P, Maron MB. Excessive sympathetic nervous system activity decreases myocardial contractility. Proc Soc Exp Biol Med. 1990;193:225231.[Medline] [Order article via Infotrieve]
41. Norris SL, Nosko M, Weir B, King EG, Grace M. Acute cardiopulmonary effects of subarachnoid hemorrhage in monkeys. Crit Care Med. 1986;14:491494.[Medline] [Order article via Infotrieve]
42. Rabb CH, Tang G, Chin S, Gianotta SL. A statistical analysis of factors related to symptomatic cerebral vasospasm. Acta Neurochir. 1994;127:2731.[Medline] [Order article via Infotrieve]
43. Ohman J, Servo A, Heiskanen O. Risk factors for cerebral infarction in good-grade patients after aneurysmal subarachnoid hemorrhage and surgery: a prospective study. J Neurosurg. 1991;74:1420.[Medline] [Order article via Infotrieve]
44.
Brouwers PJAM, Dippel DWJ, Vermeulen M, Lindsay KW,
Hasan D, van Gijn J. Amount of blood on computed tomography as an
independent predictor after aneurysm rupture.
Stroke. 1993;24:809814.
45. Lasner TM, Weil RJ, Rina HA, King TR Jr, Zager EL, Raps EC, Flamm ES. Cigarette smoking-induced increase in the risk of symptomatic vasospasm after aneurysmal subarachnoid hemorrhage. J Neurosurg. 1997;87:381384.[Medline] [Order article via Infotrieve]
46.
Adams HP, Kassell NF, Torner JC, Haley EC.
Predicting cerebral ischemia after aneurysmal
subarachnoid hemorrhage: influences of clinical
condition, CT results, and antifibrinolytic therapy.
Neurology. 1987;37:15861591.
This article has been cited by other articles:
![]() |
M. Hravnak, J. M. Frangiskakis, E. A. Crago, Y. Chang, M. Tanabe, J. Gorcsan III, and M. B. Horowitz Elevated Cardiac Troponin I and Relationship to Persistence of Electrocardiographic and Echocardiographic Abnormalities After Aneurysmal Subarachnoid Hemorrhage Stroke, November 1, 2009; 40(11): 3478 - 3484. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. W. Dunser and W. R. Hasibeder Sympathetic Overstimulation During Critical Illness: Adverse Effects of Adrenergic Stress J Intensive Care Med, September 1, 2009; 24(5): 293 - 316. [Abstract] [PDF] |
||||
![]() |
C. Ripa, F. Olivieri, and R. Antonicelli Tako-Tsubo-Like Syndrome With Atypical Clinical Presentation: Case Report and Literature Review Angiology, August 1, 2009; 60(4): 513 - 517. [Abstract] [PDF] |
||||
![]() |
I.A.C. van der Bilt, D. Hasan, W. P. Vandertop, A. A.M. Wilde, A. Algra, F. C. Visser, and G. J.E. Rinkel Impact of cardiac complications on outcome after aneurysmal subarachnoid hemorrhage: A meta-analysis Neurology, February 17, 2009; 72(7): 635 - 642. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nayate, S. A. Moore, R. Weiss, O. M. Taktakishvili, L.-H. Lin, and W. T. Talman Cardiac damage after lesions of the nucleus tractus solitarii Am J Physiol Regulatory Integrative Comp Physiol, February 1, 2009; 296(2): R272 - R279. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. A. Coghlan, B. J. Hindman, E. O. Bayman, N. M. Banki, A. W. Gelb, M. M. Todd, J. G. Zaroff, and IHAST Investigators Independent Associations Between Electrocardiographic Abnormalities and Outcomes in Patients With Aneurysmal Subarachnoid Hemorrhage: Findings From the Intraoperative Hypothermia Aneurysm Surgery Trial Stroke, February 1, 2009; 40(2): 412 - 418. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. P. Bleck Seizures, Stroke, and Other Neurologic Emergencies ACCP Crit Care Med Brd Rev, January 1, 2009; 20(0): 433 - 466. [Full Text] [PDF] |
||||
![]() |
C. R. Tomczak, A. Jelani, R. G. Haennel, M. J. Haykowsky, R. Welsh, and P. J. Manns Cardiac Reserve and Pulmonary Gas Exchange Kinetics in Patients With Stroke Stroke, November 1, 2008; 39(11): 3102 - 3106. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Bybee and A. Prasad Stress-Related Cardiomyopathy Syndromes Circulation, July 22, 2008; 118(4): 397 - 409. [Full Text] [PDF] |
||||
![]() |
H.-J. Priebe Aneurysmal subarachnoid haemorrhage and the anaesthetist Br. J. Anaesth., July 1, 2007; 99(1): 102 - 118. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. G. Zaroff, L. Pawlikowska, J. C. Miss, S. Yarlagadda, C. Ha, A. Achrol, P.-Y. Kwok, C. E. McCulloch, M. T. Lawton, N. Ko, et al. Adrenoceptor Polymorphisms and the Risk of Cardiac Injury and Dysfunction After Subarachnoid Hemorrhage Stroke, July 1, 2006; 37(7): 1680 - 1685. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Naidech Adrenoreceptor Polymorphisms and Subarachnoid Hemorrhage Stroke, July 1, 2006; 37(7): 1635 - 1635. [Full Text] [PDF] |
||||
![]() |
N. M. Banki, A. Kopelnik, M. W. Dae, J. Miss, P. Tung, M. T. Lawton, B. J. Drew, E. Foster, W. Smith, W. W. Parmley, et al. Acute Neurocardiogenic Injury After Subarachnoid Hemorrhage Circulation, November 22, 2005; 112(21): 3314 - 3319. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Naidech, K. T. Kreiter, N. Janjua, N. D. Ostapkovich, A. Parra, C. Commichau, B.-F. M. Fitzsimmons, E. S. Connolly, and S. A. Mayer Cardiac Troponin Elevation, Cardiovascular Morbidity, and Outcome After Subarachnoid Hemorrhage Circulation, November 1, 2005; 112(18): 2851 - 2856. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Schillinger Editorial Comment--Brain Natriuretic Peptide and Early Cardiac Dysfunction After Subarachnoid Hemorrhage Stroke, July 1, 2005; 36(7): 1570 - 1571. [Full Text] [PDF] |
||||
![]() |
I. S. Wittstein, D. R. Thiemann, J. A.C. Lima, K. L. Baughman, S. P. Schulman, G. Gerstenblith, K. C. Wu, J. J. Rade, T. J. Bivalacqua, and H. C. Champion Neurohumoral Features of Myocardial Stunning Due to Sudden Emotional Stress N. Engl. J. Med., February 10, 2005; 352(6): 539 - 548. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. M. van den Bergh, A. Algra, and G. J.E. Rinkel Electrocardiographic Abnormalities and Serum Magnesium in Patients With Subarachnoid Hemorrhage Stroke, March 1, 2004; 35(3): 644 - 648. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Homma and C. Grahame-Clarke Editorial Comment--Myocardial Damage in Patients With Subarachnoid Hemorrhage Stroke, February 1, 2004; 35(2): 552 - 553. [Full Text] [PDF] |
||||
![]() |
R. Jain, J. Deveikis, and B. G. Thompson Management of Patients with Stunned Myocardium Associated with Subarachnoid Hemorrhage AJNR Am. J. Neuroradiol., January 1, 2004; 25(1): 126 - 129. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. o. Cosar and C. J. O'Connor Hibernation, Stunning, and Preconditioning: Historical Perspective, Current Concepts, Clinical Applications, and Future Implications Seminars in Cardiothoracic and Vascular Anesthesia, June 1, 2003; 7(2): 115 - 140. [Abstract] [PDF] |
||||
![]() |
C. Commichau, N. Scarmeas, and S. A. Mayer Risk factors for fever in the neurologic intensive care unit Neurology, March 11, 2003; 60(5): 837 - 841. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Masuda, K. Sato, S.-i. Yamamoto, N. Matsuyama, T. Shimohama, A. Matsunaga, S. Obuchi, Y. Shiba, S. Shimizu, and T. Izumi Sympathetic Nervous Activity and Myocardial Damage Immediately After Subarachnoid Hemorrhage in a Unique Animal Model Stroke, June 1, 2002; 33(6): 1671 - 1676. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Bernstein, S. A. Mayer, and A. Magnano Neurogenic stunned myocardium in Guillain-Barre syndrome Neurology, February 8, 2000; 54(3): 759 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
Myocardial Dysfunction and Vasospasm in Subarachnoid Hemorrhage Journal Watch Neurology, July 1, 1999; 1999(701): 7 - 7. [Full Text] |
||||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1999 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |